Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Oral Cavity SCC — Definitive Treatment

Oral cavity SCC (incl. mucosal lip) Early T1–2 N0 Resection of primary ± neck dissection / SLN surgery preferred Definitive RT alternative Resectable locally advanced T3 N0 · T1–3 N1–3 · T4a N0–3 Surgery + neck dissection preferred Neoadjuvant pembrolizumab PD-L1 CPS ≥1, except N3 — KEYNOTE-689 ↗ Surgery → RT + pembrolizumab (+ cisplatin if ECE / + margin) → adjuvant pembrolizumab Clinical trial Adjuvant therapy by pathologic risk No positive node, no adverse features observe One node / pN1, no other risk consider RT Extranodal extension ± positive margin chemoRT (cisplatin) Positive margin re-resect, or chemoRT / RT Other risk features RT ± concurrent chemo